Barclays PLC
- SEC CIK
- 0000312069
- Latest filing
- Aug 14, 2026
INBX holding history
Inhibrx Biosciences, Inc. in every 13F filed by Barclays PLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
INBX overviewAll 13F holders of INBXFull Q2 2026 holdings
- Shares (Q2 2026)
- 2,347
- Value
- $222.4K
- % of portfolio
- <0.1%
- Quarters held
- 18
- Since Q1 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 2,347 | $222.4K | <0.1% | +680+40.8% | Added | Holders |
| Q1 2026 | 1,667 | $112.1K | <0.1% | −20,212−92.4% | Reduced | Holders |
| Q4 2025 | 21,879 | $1.73M | <0.1% | +8,411+62.5% | Added | Holders |
| Q3 2025 | 13,468 | $453.6K | <0.1% | −3,696−21.5% | Reduced | Holders |
| Q2 2025 | 17,164 | $244.9K | <0.1% | +3,881+29.2% | Added | Holders |
| Q1 2025 | 13,283 | $185.8K | <0.1% | −5,558−29.5% | Reduced | Holders |
| Q4 2024 | 18,841 | $290.2K | <0.1% | +2,786+17.4% | Added | Holders |
| Q3 2024 | 16,055 | $251.4K | <0.1% | +12,476+348.6% | Added | Holders |
| Q2 2024 | 3,579 | $50.7K | <0.1% | −278,724−98.7% | Reduced | Holders |
| Q1 2024 | 282,303 | $9.87M | <0.1% | +193,438+217.7% | Added | Holders |
| Q4 2023 | 88,865 | $3.10M | <0.1% | +25,688+40.7% | Added | Holders |
| Q3 2023 | 63,177 | $1.15M | <0.1% | −5,357−7.8% | Reduced | Holders |
| Q2 2023 | 68,534 | $1.76M | <0.1% | +3,873+6.0% | Added | Holders |
| Q1 2023 | 64,661 | $1.19M | <0.1% | −41,942−39.3% | Reduced | Holders |
| Q4 2022 | 106,603 | $2.56M | <0.1% | +19,525+22.4% | Added | Holders |
| Q3 2022 | 87,078 | $1.52M | <0.1% | +83,981+2,711.7% | Added | Holders |
| Q2 2022 | 3,097 | $38.0K | <0.1% | −1,481−32.4% | Reduced | Holders |
| Q1 2022 | 4,578 | $102.0K | <0.1% | +4,578 | New | Holders |